Baidu
map

Cell Res:中科院杨巍维研究组揭示癌细胞适应氧化应激的重要机制

2017-01-04 佚名 生物谷

近日,中科院上海生命科学研究院生化细胞所杨巍维研究组在国际学术期刊Cell Research上发表了一项最新研究进展,他们证实线粒体PKM2可通过稳定Bcl2调节氧化应激诱导的细胞凋亡。由于癌基因刺激、代谢活性增加和线粒体功能紊乱等因素,癌细胞的活性氧水平高于正常细胞。在持续的氧化应激情况下,癌细胞通过一系列机制得以适应,不仅激活ROS清除系统,也会抑制细胞凋亡。许多研究表明癌细胞的这种适应性会


近日,中科院上海生命科学研究院生化细胞所杨巍维研究组在国际学术期刊Cell Research上发表了一项最新研究进展,他们证实线粒体PKM2可通过稳定Bcl2调节氧化应激诱导的细胞凋亡

由于癌基因刺激、代谢活性增加和线粒体功能紊乱等因素,癌细胞的活性氧水平高于正常细胞。在持续的氧化应激情况下,癌细胞通过一系列机制得以适应,不仅激活ROS清除系统,也会抑制细胞凋亡。许多研究表明癌细胞的这种适应性会促进恶性转化、转移和对抗癌药物的抵抗,因此理解ROS适应机制对于杀死癌细胞解决耐药问题是非常重要的。

PKM2能够催化糖酵解的最后一步,对于肿瘤细胞增殖也非常重要。在这项研究中,研究人员发现PKM2在氧化应激条件下会转定位到线粒体,在线粒体与Bcl2结合并将其磷酸化。这种磷酸化修饰会阻止Bcl2与Cul3为基础的E3连接酶的结合,防止Bcl2的降解。研究人员还发现分子伴侣HSP90α1是PKM2发挥该功能所必需的一个分子,HSP90α1的ATP酶活性可引起PKM2发生构象变化,促进PKM2与Bcl2的结合。将野生型Bcl2替换为磷酸化缺陷的突变体会增加胶质瘤细胞对氧化应激诱导细胞凋亡的敏感性,并损伤原位移植模型中的脑肿瘤形成。

值得注意的是,单独合成PKM2与Bcl2结合的肽段能够破坏PKM2与Bcl2的相互结合促进Bcl2降解,损伤脑肿瘤生长。此外,Bcl2 T69磷酸化水平,构象改变的PKM2和Bcl2蛋白在人类胶质母细胞瘤患者标本中彼此关联,Bcl2 T69磷酸化水平和构象改变的PKM2还与胶质瘤恶性程度等级以及肿瘤预后相关。

这些结果揭示了癌细胞可以在氧化应激情况下通过定位在线粒体的PKM2与Bcl2之间的相互作用抑制细胞凋亡,表明PKM2在癌细胞对ROS的适应性中具有至关重要的作用,因此HSP90-PKM2-Bcl2可能是治疗胶质母细胞瘤的一个潜在靶点。

原始出处

Ji Liang1,2,3,*, Ruixiu Cao1,2,3,*, Xiongjun Wang1,2,3, Yajuan Zhang1,2,3, Pan Wang1,2,3, Hong Gao1,2,3, Chen Li1, Fan Yang4, Rong Zeng1, Ping Wei5, Dawei Li6, Wenfeng Li7 and Weiwei Yang.Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2.Cell Res.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862567, encodeId=e32c186256e61, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 23 02:24:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959972, encodeId=8d7919599e2a0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 23 14:24:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869713, encodeId=56091869e13af, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 28 23:24:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252175, encodeId=a69b12521e511, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 06 13:24:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445137, encodeId=1307144513eec, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 06 13:24:00 CST 2017, time=2017-01-06, status=1, ipAttribution=)]
    2017-11-23 gous
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862567, encodeId=e32c186256e61, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 23 02:24:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959972, encodeId=8d7919599e2a0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 23 14:24:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869713, encodeId=56091869e13af, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 28 23:24:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252175, encodeId=a69b12521e511, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 06 13:24:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445137, encodeId=1307144513eec, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 06 13:24:00 CST 2017, time=2017-01-06, status=1, ipAttribution=)]
    2017-05-23 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862567, encodeId=e32c186256e61, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 23 02:24:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959972, encodeId=8d7919599e2a0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 23 14:24:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869713, encodeId=56091869e13af, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 28 23:24:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252175, encodeId=a69b12521e511, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 06 13:24:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445137, encodeId=1307144513eec, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 06 13:24:00 CST 2017, time=2017-01-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1862567, encodeId=e32c186256e61, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 23 02:24:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959972, encodeId=8d7919599e2a0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 23 14:24:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869713, encodeId=56091869e13af, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 28 23:24:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252175, encodeId=a69b12521e511, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 06 13:24:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445137, encodeId=1307144513eec, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 06 13:24:00 CST 2017, time=2017-01-06, status=1, ipAttribution=)]
    2017-01-06 yxch36
  5. [GetPortalCommentsPageByObjectIdResponse(id=1862567, encodeId=e32c186256e61, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Nov 23 02:24:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959972, encodeId=8d7919599e2a0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 23 14:24:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869713, encodeId=56091869e13af, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 28 23:24:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252175, encodeId=a69b12521e511, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 06 13:24:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445137, encodeId=1307144513eec, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jan 06 13:24:00 CST 2017, time=2017-01-06, status=1, ipAttribution=)]

相关资讯

Nature:进一步证明脂肪会为癌细胞扩散“铺路”

导读 12月26日在线发表在Nature上的文章发现除了提供肿瘤所需的“燃料”,脂肪还会为癌细胞扩散“铺路”。该研究揭示了被称为淋巴管的这种肿瘤扩散“路径”的发展需要增加脂肪的利用。这项发现为开发通过靶向脂肪利用,限制癌症中淋巴管生长的治疗手段铺平了道路。

Nat Med:“饥饿”疗法能够有效抑制儿童常见淋巴瘤的恶化

(图片摘自www.sciencealert.com) 最新一项研究指出,“饥饿”疗法能够有效缓解一类常见的儿童淋巴瘤的恶化。 基于在小鼠水平的试验结果,研究者们认为有规律的节食处理能够有效抑制两类急性淋巴瘤(ALL)的恶化,他们认为这一研究成果能够应用于人体的癌症治疗。 ALL是指人体由于过量产生未成熟的白血球(即成淋巴细胞),并逐步代替体内原有的成熟白细胞引发的癌症。虽然这种疾病也在成

Nature:脂肪是叛徒!为癌细胞扩散铺平道路

癌细胞一步步扩散到身体的其他部位,其方式是通过为自己“铺平道路”。于12月26日发表在《Nature》上的一项研究中,一个由和佛兰德斯生物技术研究所和比利时鲁汶大学(VIB-KU Leuven)的Peter Carmeliet博士领导的全球性跨学科研究团队发现,脂肪利用率增多是这些“道路”(即称为淋巴管的一种特殊血管)发育和生长的必要条件。这项研究为以靶向脂肪开发出限制淋巴管在癌症情况下增长铺平了

JCI:癌细胞的“变身”可促进肿瘤的生长

由于恶性肿瘤在体内扩散的较快,所以它们需要不断提供血液供应,来传递供它们生长的氧气和营养物质。现在, 由美国佛罗里达大学(UF)带领的一个研究小组,已经确定了一些肿瘤是如何增强自身血液供应的。相关研究结果 、发表在最近的《Journal of Clinical Investigation》杂志。这项研究表明,某些癌细胞可以转化为血管支架细 胞,促进肿瘤的生长。该研究结果进一步揭示了肿瘤是如何能够保

CAR-T疗法明年有望进入临床应用

如果存在一种类似于灭癌银弹一样的东西,它将以你体内的那些癌细胞为唯一目标,而不会伤害你体内的其它细胞。这种展望来源于一种全新的免疫疗法,它被科学家们称为CAR-T细胞疗法。这种实验性癌症免疫疗法借助生物工程改造的细胞对癌细胞进行杀灭,而且以癌细胞为唯一目标。目前在全世界范围内有超多100多个CAR-T细胞疗法临床试验正在进行当中,美国食品和药品监督管理局有希望同意进行CAR-T细胞疗法。研究人员目

Nat Genet:突破!科学家发现相同肿瘤中存在不同遗传复杂性的癌细胞

图片来源:medicalxpress.com 近日,一项刊登于国际杂志Nature Genetics上的研究报告中,来自美国洛杉矶希达-西奈(Cedars-Sinai)医学院的研究人员通过研究在食管肿瘤的组织样本中鉴别出了2000多个基因突变,从而详细阐述了癌症的复杂性,本文研究表明,单一肿瘤的不同区域或许具有多种遗传模式。 研究者指出,本文研究能够帮助解释为何靶向特殊遗传缺陷反而难以有效

Baidu
map
Baidu
map
Baidu
map